{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004120","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.000714+00:00","generated_at":"2026-06-20T17:39:52.326392+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere reports preliminary Q4 rev ~$52M; sparsentan PDUFA Feb 17, 2023","bullets":["Preliminary net product sales Q4 2022 ~$52M; full year 2022 net product sales ~$201M, total revenue $212M.","Ended 2022 with ~$450M in cash, cash equivalents, and marketable securities.","FDA PDUFA for sparsentan in IgAN set for Feb 17, 2023; potential Q1 2023 launch if approved.","Phase 3 PROTECT (IgAN) topline confirmatory results expected Q4 2023; DUPLEX (FSGS) topline Q2 2023.","Phase 3 trial for pegtibatinase (HCU) to begin H2 2023; RESTORE study for CTX completion expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004120","json":"https://secwatch.observer/filing/0001193125-23-004120.json","markdown":"https://secwatch.observer/filing/0001193125-23-004120.md","text":"https://secwatch.observer/filing/0001193125-23-004120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/d436263d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:39:52.326392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51e5d868e7015ca6e89d93ea8e708ba510bf5b69","claim":"Travere Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue approximately $52 million.","evidence_excerpt":"the Company expects net product sales for the fourth quarter of 2022 to be approximately $52 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"approximately $52 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"68cc026305d23aa49be73c4694154e2792b2ce27","claim":"Travere Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $212 million.","evidence_excerpt":"For the fiscal year 2022, the Company expects total revenue of $212 million, inclusive of approximately $201 million in net product sales and approximately $11 million in licensing and collaboration revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$212 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}